BACKGROUND: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. There is renewed interest in refined approaches to brain stimulation, particularly for treatment resistant major depressive disorder (MDD). METHODS: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria. Lines of Treatment were identified based on criteria that included evidence and expert clinical support. This section on "Neurostimulation Therapies" is one of 5 guidelines articles. RESULTS: Among the four forms of neurostimulation reviewed in this section, electroconvulsive therapy (ECT) has the most extensive evidence, spanning seven decades. Repetitive transcranial magnetic (rTMS) and vagus nerve stimulation (VNS) have been approved to treat depressed adults in both Canada and the United States with a much smaller evidence base. There is also emerging evidence that deep brain stimulation (DBS) is effective for otherwise treatment resistant depression, but this is an investigational approach in 2009. LIMITATIONS: Compared to other modalities for the treatment of MDD, the data based is limited by the relatively small numbers of randomized controlled trials (RCTs) and small sample sizes. CONCLUSIONS: There is most evidence to support ECT as a first-line treatment under specific circumstances and rTMS as a second-line treatment. Evidence to support VNS is less robust and DBS remains an investigational treatment.

4.1.3 维持期 抑郁症具有高复发性,尤其是≥3次抑郁发作及慢性抑郁患者,多个指南明确提出应该继续进行维持期治疗。如合并抑郁症家族史、起病早、症状残存、持续应激等危险因素时,需考虑进行维持治疗。WHO建议对单次发作、症状轻、间歇期长(≥5年)者,一般可不维持治疗,但也有较多专家认为首次抑郁症发作也应维持6~8个月的治疗[9]。维持治疗的时间长短各指南论述不一,差异较大,应根据患者的综合情况个体化考虑。一般倾向至少持续2~3年,多次复发者主张长期维持治疗。维持治疗期间应定期进行病情及疗效评估,关注早期复发征象,监测药物不良反应。长期维持治疗,如病情稳定,各方面评估良好者,可考虑缓慢减药直至停药。减药期间应加强监测,一旦发现早期复发征象,应立即恢复原先治疗剂量。国内外多个指南推荐,维持期建议加强心理治疗,如认知行为治疗、团体自助模式等,纠正错误的观点及认知,建立积极的自助、社交心态,可有效降低抑郁症复发率,改善疾病预后。
Depression is a common mood disorder, with a high incidence and prevalence, while the overall diagnosis and treatment rate are low.Even if patients attained the initial clinical cure, there is still a high risk of depression recurrence, of which a great part may turn into self-mutilation or even suicide.Taking antidepressants as the most preferred treatment of moderate and major depression is recommended by almost all clinical treatment guidelines at home and abroad currently.At the same time, the concept of depression treatment is changing gradually from the initial single-mode drug therapy for symptom control to a comprehensive, individualized, quantitative treatment model.Promising psychological treatment, physical therapy and other alternative and complementary treatments are developing quickly.
由于不了解你女朋友的具体情况,我不好给出意见。从你的另外一个帖子里,我能够感到你对她的关心、你的焦急,但是我也想提醒你,想要关心抑郁症患者的家属,首先要学会关心自己。一个人可以轻易学会不在乎,但学会在乎,却需要付出千百倍的勇气和努力。我的女朋友在陪伴我的时候,自己也经历了不少痛苦。她后来通过咨询心理医生应该怎么照顾我,来调整好了自己的情绪。我想告诉你的是,你要对抑郁症有所准备(教育自己,学习一些这方面的知识),即使你是一个很乐观和活泼的人。陪伴抑郁症患者很消耗人的能量。我给你推荐两个专业团队的回答。https://www.zhihu.com/question/54853415 这个问题中 ID为“简单心理”的回答,这里面你可以读到一些故事(有些故事比较恐怖,你不必被吓到,结合你自己的情况考虑,你女友未必那么严重);Knowyourself这个团队写的http://www.toutiao.com/i6402008917009760769/ “因为爱你,我想陪着你不快乐|研究:抑郁会在伴侣间传染” 。你能来问这个问题,说明你充满了爱心,我为你点赞!祝你女友能走出这段阴霾。
抑郁症以往被划分为情感性精神病、其它类型的疾病均被划分为神经 症。抑郁症是一种持久的心境低落状态,常伴有焦虑、躯体不适感和睡眠障 碍,患者有治疗要求,而无明显的运动障碍、以及幻觉、幻想、思维和行为 紊乱等精神特征,生活能力无明显影响;神经症是一組表现心情抑郁、烦恼、 紧张、恐怖、疑病、强迫症状、分离和转换症状等,除意症表现为短的发作 性症状外, 一般病程迁延可达数年或数十年,可分为恐怖性神经症、焦虑性 神经症、强迫性神经症、抑郁性神经症、癔症、疑病性神经症、神经哀弱、 其它神经症(人格解体神经症、躯体化障碍、职业性如书写痉挛)等。依据中 医理论,抑郁症、焦虑症统称为精神和心理障碍性疾病,是由于植物神经功 能紊乱而导致心境低落、焦虑、失眠多梦,幻觉、妄想、思维和行为紊乱等 精神病特征。中医认为这些症状是因情志不遂,忧思悲怒,起居不慎,饮食 不节而造成。西医治疗多采取化学药物治疗,其疗效不稳定,副作用大;而中药以其毒性小,长期服用安全,越来越多的被人们认识用于治疗精神方面 的疾病。

Brintellix通用名Vortioxetine,是一种调节和促进血清素分泌类的药物,属于非典型性抗抑郁症药物,它的机制目前还不完全清楚,但是发现它同时起到血清素再摄取抑制剂、去甲肾上腺素再摄取抑制剂、5-HT 1A受体激动剂、5-HT 1B受体部分激动剂等功能。武田制药声称,这款药物是目前唯一通过这种综合性的功能来促进血清素水平的药物,虽然每一种功能对其发挥抗抑郁作用的贡献有多大,目前为止还不是很清楚,此药除了能够改善患者的情绪外,临床研究显示还能改善认知功能,对于目前市场上销售的抗抑郁症药物来说,这可以称得上是一种具有进步性的药物。此药由武田和丹麦的灵北制药公司共同销售,在这笔交易中武田支付灵北制药4000万美元的先期付款,另外总计高达3.45亿美元的里程碑付款。2013年先后在美国和欧盟上市,预测2017年销售额8.45亿美元, 2021年销售额为17.5亿美元。
×